SCHEMBL4100415

SCHEMBL4100415

C[C@H]1CN(Cc2cccc(-c3cccc(CNC(=O)c4ccc5c(c4)OCO5)c3)n2)CCN1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 20/20 1.00
CHRM1 P11229 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4100580 0.95 CHRM3 (0.90) CHRM3CHRM1
SCHEMBL13649181 0.89 CHRM3 (1.00) CHRM3CHRM1
SCHEMBL13649178 0.89 CHRM3 (1.00) CHRM3CHRM1
SCHEMBL4100573 0.86 CHRM3 (0.76) CHRM3CHRM1
SCHEMBL4105238 0.85 CHRM3 (0.74) CHRM3CHRM1
SCHEMBL4100583 0.84 CHRM3 (0.73) CHRM3CHRM1
Trifluoroacetic Acid SCHEMBL4093186 0.84 CHRM3 (0.89) CHRM3CHRM1
SCHEMBL4109872 0.84 CHRM3 (1.00) CHRM3CHRM1
Trifluoroacetic Acid SCHEMBL4100257 0.84 CHRM3 (0.89) CHRM3CHRM1
Trifluoroacetic Acid SCHEMBL4098262 0.84 CHRM3 (0.89) CHRM3CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253908-A1 NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED 2009-10-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253908-A1 NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS CHRM3, CHRM2, CHRNA3 CHRM3 1/4885CHRM1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.